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Abstract 
Background and Purpose: Animal toxins have contributed significantly to our understanding of the 
neurobiology of receptors and ion channels. We studied the venom of the coral snake Micrurus fulvius 
fulvius and identified and characterized the structure and pharmacology of a new homodimeric 
neurotoxin, fulditoxin, that exhibited novel pharmacology at nicotinic ACh receptors (nAChRs). 
Experimental Approach: Fulditoxin was isolated by chromatography, chemically synthesized, its structure 
determined by X-ray crystallography, and its pharmacological actions on nAChRs characterized by organ 
bath assays and two-electrode voltage clamp electrophysiology. Key Results: Fulditoxin's distinct 1.95-Å 
quaternary structure revealed two short-chain three-finger α-neurotoxins (α-3FNTxs) non-covalently 
bound by hydrophobic interactions and an ability to bind metal and form tetrameric complexes, not 
reported previously for three-finger proteins. Although fulditoxin lacked all conserved amino acids 
canonically important for inhibiting nAChRs, it produced postsynaptic neuromuscular blockade of chick 
muscle at nanomolar concentrations, comparable to the prototypical α-bungarotoxin. This neuromuscular 
blockade was completely reversible, which is unusual for snake α-3FNTxs. Fulditoxin, therefore, interacts 
with nAChRs by utilizing a different pharmacophore. Unlike short-chain α-3FNTxs that bind only to muscle 
nAChRs, fulditoxin utilizes dimerization to expand its pharmacological targets to include human neuronal 
α4β2, α7, and α3β2 nAChRs which it blocked with IC50 values of 1.8, 7, and 12 μM respectively. 
Conclusions and Implications: Based on its distinct quaternary structure and unusual pharmacology, we 
named this new class of dimeric Micrurus neurotoxins represented by fulditoxin as Σ-neurotoxins, which 
offers greater insight into understanding the interactions between nAChRs and peptide antagonists. 
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Background and Purpose:  
Animal toxins have contributed significantly to our understanding of the neurobiology of receptors 
and ion channels. We studied the venom of the coral snake Micrurus fulvius fulvius and identified 
and characterized the structure and pharmacology of a new homodimeric neurotoxin, fulditoxin, 
that exhibited novel pharmacology at nicotinic ACh receptors (nAChRs). 
Experimental Approach:  
Fulditoxin was isolated by chromatography, chemically synthesized, its structure determined by X-
ray crystallography, and its pharmacological actions on nAChRs characterized by organ bath assays 
and two-electrode voltage clamp electrophysiology. 
Key Results:  
Fulditoxin's distinct 1.95-Å quaternary structure revealed two short-chain three-finger α-
neurotoxins (α-3FNTxs) non-covalently bound by hydrophobic interactions and an ability to bind 
metal and form tetrameric complexes, not reported previously for three-finger proteins. Although 
fulditoxin lacked all conserved amino acids canonically important for inhibiting nAChRs, it 
produced postsynaptic neuromuscular blockade of chick muscle at nanomolar concentrations, 
comparable to the prototypical α-bungarotoxin. This neuromuscular blockade was completely 
reversible, which is unusual for snake α-3FNTxs. Fulditoxin, therefore, interacts with nAChRs by 
utilizing a different pharmacophore. Unlike short-chain α-3FNTxs that bind only to muscle 
nAChRs, fulditoxin utilizes dimerization to expand its pharmacological targets to include human 




Conclusions and Implications:  
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Based on its distinct quaternary structure and unusual pharmacology, we named this new class of 
dimeric Micrurus neurotoxins represented by fulditoxin as Σ-neurotoxins, which offers greater 
insight into understanding the interactions between nAChRs and peptide antagonists. 
 
Abbreviations: 3FTx, three-finger toxin; AA, amino acid; Boc, tertbutoxycarbonyl; CCh, 
carbachol; CBCM, chick biventer cervicis muscle; EbTx-a, erabutoxin-a; EbTx-b, erabutoxin-b; 
EC50, half-maximal effective concentration; ESI-MS, electrospray ionization MS; Fmoc, 9-
fluorenylmethoxycarbonyl; IC50, half-maximal inhibitory concentration; MFV, Micrurus fulvius 
fulvius venom; nFulditoxin, native fulditoxin; RP-HPLC, reversed-phase HPLC; sFulditoxin, 
synthetic fulditoxin; TEVC, two-electrode voltage clamp; α-3FNTx, three-finger α-neurotoxin; α-
BgTx, α-bungarotoxin; α-CbTx, α-cobratoxin. 
 
What is already known 
• Snake three-finger α-neurotoxins competitively and selectively inhibit muscle and neuronal 
nAChRs. 
• Their selectivity for nAChR subtypes is defined by conserved functionally invariant amino acid 
residues. 
What does this study add 
• Fulditoxin represents a novel dimeric three-finger α-neurotoxin family which lacks canonical 
functionally invariant residues. 
• Unlike monomeric short-chain α-neurotoxins, fulditoxin inhibits α7, α3β2, α4β2, and muscle 
nAChRs.  
What is the clinical significance 





1  INTRODUCTION 
The identification and characterization of the first neurotransmitter receptor protein, the nicotinic 
ACh receptor (nAChR), was a significant milestone in molecular pharmacology, which was 
4 
 
possible only with the concurrent discovery of α-bungarotoxin (α-BgTx), the prototypical snake 
neurotoxin antagonist of the receptor (Changeux, 2012). The nAChR is a heteropentameric, 
allosteric receptor formed by homologous subunits around a central transmembrane cation channel, 
with extracellular ACh binding sites at subunit interfaces. The combinatorial assembly of a number 
of different subunits (α1 to α10, β1 to β4, δ, γ, or ε) generates a diversity of receptor subtypes with 
distinct physiological, pharmacological, and clinical significance. At the neuromuscular junction, 
the postsynaptic nAChR is of the (α1)2β1γδ (fetal) or (α1)2β1δε (adult) subunit stoichiometry. 
Neuronal nAChRs are composed of various combinations of α2 to α10 and β2 to β4 subunits and 
play significant physiological roles in the CNS including cognition, memory, and addiction and are 
involved in cellular signalling pathways at extraneuronal locations (see Bouzat & Sine, 2018; 
Wonnacott, Bermudez, Millar, & Tzartos, 2018).  
The snake three-finger α-neurotoxins (α-3FNTxs) constitute one of the largest groups within 
the three-finger toxin (3FTx) family, characterized by three finger-like β-stranded loops converging 
at a disulfide-rich hydrophobic core (Kessler, Marchot, Silva, & Servent, 2017; Tsetlin, 2015). 
Despite this conserved protein fold, 3FTxs have markedly different biological targets, illustrating 
functional divergence in evolution (Kini & Doley, 2010; Tsetlin, 2015). α-3FNTxs are classified 
into short-chain (Type I; 60-62 amino acid [AA] residues with four disulfide bonds) and long-chain 
(Type II; 66-75 AA residues with five disulfide bonds) α-3FNTxs. Both subfamilies bind with high 
affinity (KD 10−10–10−11 M) to muscle nAChRs, whereas long-chain, but not short-chain, α-3FNTxs 
bind with high affinity (KD 10−8–10−9 M) to neuronal α7, α9, and α9/α10 nAChRs (McIntosh, 
Absalom, Chebib, Elgoyhen, & Vincler, 2009). Furthermore, some long-chain α-3FNTxs also 
inhibit the structurally homologous GABAA receptors (KD 5–20−6 M; Kudryavtsev et al., 2015). 
Although most α-3FNTxs bind irreversibly to nAChRs, novel α-3FNTxs that produced rapid and 
completely reversible blockade of muscle nAChRs have also been described (Harvey, Hider, 
Hodges, & Joubert, 1984; Nirthanan, Charpantier, et al., 2003).  
The short-chain α-3FNTx, erabutoxin-a (EbTx-a), and long-chain α-3FNTxs, α-cobratoxin 
and α-BgTx use a common core of canonical AA residues in loops I and II, in addition to specific 
combinations of conserved AA residues for binding to muscle and neuronal α7 nAChRs (Antil-
Delbeke et al., 2000; Teixeira-Clerc, Menez, & Kessler, 2002; see Figure S1). Interestingly, in Type 
III α-3FNTxs (Jackson et al., 2013) and Ω-neurotoxins (Hassan-Puttaswamy, Adams, & Kini, 
2015), two unrelated classes of nAChR antagonists, almost all conserved functional AA residues of 
α-3FNTxs are replaced, revealing that these toxins may utilize alternative functional sites to bind to 
a common molecular target within nAChRs. 
Although most 3FTxs are monomers, a small number exist as dimers. κ-Bungarotoxin (κ-
BgTx) is a long-chain α-3FNTx homodimer, which binds with high affinity to α3β2 and weakly 
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to α7 and α4β2 nAChRs, but not to muscle nAChRs (Dewan, Grant, & Sacchettini, 1994). We 
described haditoxin (Ophiophagus hannah), a short-chain α-3FNTx homodimer that inhibits 
muscle α1β1γδ and neuronal α7, α3β2, and α4β2 nAChRs (Roy et al., 2010) and the first 
covalently linked heterodimeric α-3FNTx, irditoxin (Boiga irregularis), that exhibits taxa-
specific neurotoxicity for avian α1β1γδ nAChRs (Pawlak et al., 2009). A covalently bound α-
cobratoxin homodimer (Naja kaouthia) retains the monomeric α-cobratoxin's ability to inhibit 
α1β1γδ and α7 nAChRs, but additionally, inhibits α3β2 nAChRs (Osipov et al., 2008; Osipov et 
al., 2012). All these dimers share functionally invariant AA residues with short- and long-chain 
α-3FNTxs. Thus, dimeric α-3FNTxs constitute a structurally heterogeneous group of toxins 
exhibiting novel structural conformations which enables them to diversify their receptor 
specificity (Tsetlin, 2015). 
Human envenomation by Micrurus coral snakes causes high mortality due to neurotoxicity 
attributed to α-3FNTxs and phospholipase-A2 β-neurotoxins (Kitchens & Van Mierop, 1987). 
Micrurus 3FTxs exhibit significant sequence diversity as observed in transcriptomic analyses of 
their venom glands (Correa-Netto et al., 2011; Guerrero-Garzon et al., 2018; Margres, Aronow, 
Loyacano, & Rokyta, 2013); and they lack the conserved functional AA residues from previously 
characterized clades of 3FTxs, providing an impetus to investigate novel Micrurus toxins 
(Dashevsky & Fry, 2018). 
Here, we describe the identification, and pharmacological and structural characterization of a 
dimeric α-3FNTx, fulditoxin, from Mic- rurus fulvius fulvius venom. The 1.95-Å crystal structure 
of fulditoxin revealed a homodimer of short-chain α-3FNTxs non-covalently bound by 
hydrophobic interactions, with the ability to form a tetra- meric complex in the presence of zinc 
ions (Zn2+), exhibiting a unique metal-binding capability not previously reported for 3FTxs. 
Interest- ingly, despite lacking all the functionally important AA residues criti- cal for α-3FNTx 
interaction with nAChRs, fulditoxin produced potent, but completely reversible, postsynaptic 
neuromuscular blockade, as well as broad spectrum inhibition of α1β1δε, α4β2, α7, and α3β2 
nAChRs. 
 
2 METHODS  
2.1 Animal experimentation protocols 
Domestic chicks (Gallus gallus domesticus) were purchased from Chew’s Agricultural Pte Ltd 
(Singapore; ISO9001 certified) and deliv- ered on the day of experimentation and killed by 
exposure to 100% carbon dioxide. All experiments were conducted in accordance with Protocol 
103/08A approved by the Institutional Animal Care and Use Committee (IACUC) of the National 
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University of Singapore which conforms to the World Health Organization’s International Guiding 
Principles for Animal Research (Howard-Jones, 1985), adapted by the Council for International 
Organizations of Medical Sciences in 1985. 
For electrophysiological studies using the Xenopus oocyte expression system, all experiments on 
Xenopus laevis frogs conformed to the Geneva Canton Rules on Animal Experimentation 
(Accreditation # G171/3551) and the RMIT University Animal Ethics committee (Protocol # 1222, 
1223). Female X. laevis frogs were sourced from the Centre de Resources Biologiques (Rennes, 
Cedex, France) and maintained in an aquarium as approved by the Ethics Committee for Animal 
Experimentation (Swiss Academy of Medical Sciences); and from Nasco (Fort Atkinson, WI, USA) 
and housed in the RMIT Aquatic Facility. A maximum of three frogs were kept in purpose-built 10 
L tanks at 20-26°C with 12 h light/dark cycle within. Electrophysiological experiments were 
performed using oocytes obtained from three ~5-year old frogs. Frogs were anaesthetized with 1.7 
mg⋅mL-1 ethyl 3-aminobenzoate methanesulfonate (pH 7.4 with NaHCO3), and for post-surgery 
recovery, animals were placed in fresh water at a level below the nostrils. Frogs were left to recover 
for a minimum of four months between surgeries. Terminal anaesthesia with 5.0 mg⋅mL-1 ethyl 3-
aminobenzoate methanesulfonate (pH 7.4 with NaHCO3) was performed on frogs at the sixth 
surgery.   
Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, 
Cuthill, Emerson, & Altman, 2010; McGrath, Drummond, McLachlan, Kilkenny, & Wainwright, 
2010) and with the recommendations made by the British Journal of Pharmacology. 
 
2.2  Chromatographic purification of proteins from Micrurus fulvius venom 
 
The isolation and purification of fulditoxin from crude Micrurus fulvius venom (MFV) was carried 
out using established protocols in our laboratory (Hassan-Puttaswamy, Adams, & Kini, 2015; 
Pawlak et al., 2009; Roy et al., 2010). Crude MFV (50 mg dissolved in 1-ml MilliQ water and 
filtered using a 0.45-μm syringe filter) was loaded onto a Superdex 30 Hiload size-exclusion 
chromatography column, equilibrated with 50-mM Tris-hydrochloric acid (Tris–HCl) buffer (pH 
7.4), and proteins were eluted with the same buffer using an ÄKTA purifier system (GE 
Healthcare, Little Chalfont, UK). Fractions containing the protein of interest were further purified 
by reversed phase-HPLC (RP-HPLC) using a Jupiter C18 preparative column that was equilibrated 
with 0.1% (v/v) TFA. Proteins were eluted with a linear gradient of 80% (v/v) MeCN in 0.1% 
(v/v) TFA. Elution of proteins was monitored at 280 and 215 nm.   
 




2.3.1 Electrospray ionization-MS  
 
The molecular mass and homogeneity of the purified protein were determined by injecting the 
protein samples into an API-300 liquid chromatography-tandem MS system (PerkinElmer Life 
Sciences, Massachusetts, USA) as described previously (Roy et al., 2010). Ion spray, orifice and 
ring voltages were set at 4600, 50 and 350 V respectively. Nitrogen was used as the nebulizer and 
curtain gas. A Shimadzu LC-10 AD pump was used for solvent delivery (50% (v/v) MeCN in 0.1% 
(v/v) formic acid) at a flow rate of 40 μL⋅min-1. Analyst software (PerkinElmer Life Sciences, MA, 
USA) was used to analyse and deconvolute the raw MS data. Fractions that showed the expected 
molecular mass of fulditoxin were pooled and lyophilized.  
 
2.3.2 Capillary zone electrophoresis  
 
The homogeneity of purified fulditoxin was assessed by capillary zone electrophoresis which was 
performed on a BioFocus3000 system (Bio-Rad, Foster City, CA, USA). The native protein was 
dissolved in MilliQ water (1.9 μg⋅μL-1) and injected into a 25 μm x 17 cm coated capillary under a 
pressure mode (5 psi⋅s-1) and run in 0.1 M phosphate buffer (pH 2.5) under 18 kV at 20°C for 7 
min. Migration of the protein sample was monitored at 200 nm. 
 
2.4 N-terminal AA sequencing of fulditoxin 
 
Amino terminal sequencing of the native fulditoxin (nFulditoxin) and peptides derived from 
chemical digestion was performed by automated Edman degradation using a Procise Model 494 
pulsed liquid-phase sequencer (PerkinElmer Life Sciences, Massachusetts, USA) with an online 
785 A phenylthiohydantoin derivative analyser. The phenylthiohydantoin Aas were subsequently 
identified by map- ping the respective separation profiles with the standard 
chromatogram. 
 
2.4.1 Protein reduction and alkylation 
 
Lyophilized protein (1.04 mg) was dissolved in 520 μl of denaturing buffer (0.13 mol-L−1 of Tris–
HCl, 1 mmol-L−1 of EDTA, 6 mol-L−1 of guanidine-HCl, pH 8.5). β-Mercaptoethanol (1.05 μl) was 
added, and the solution was incubated under nitrogen at room temperature for 2 hr. The alkylating 
agent, 4-vinylpyridine (4.82 μl), was subsequently added and the solution was incubated under 
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nitrogen for another 3 hr at room temperature. After the reaction, the S-pyridylethylated pro- tein 
was separated from the reaction mixture by RP-HPLC on a Jupiter C18 semi-preparative column 
using a linear gradient of 80% MeCN in 0.1% TFA at a flow rate of 2 ml-min−1. The molecular 
mass of the S-pyridylethylated protein was determined by electrospray ionization-MS (ESI-MS). 
 
2.4.2 Chemical cleavage 
 
The S-pyridylethylated protein was subjected to chemical cleavage at the  C-terminus  of  
methionine  residues  with  cyanogen  bromide (CNBr).  The  S-pyridylethylated  protein  (500  μg)  
was  dissolved  in 250 μl of 70% TFA to which 5 μl of β-mercaptoethanol was added. A 200-fold 
molar excess  (over methionine residues) of  CNBr  in  70% TFA was added to make a final protein 
concentration of 1 mg-ml−1. After 24 hr of incubation in the dark at room temperature, 10 volumes 
of MilliQ water was added to the reaction mixture and lyophilized. Lyophilized sample containing 
cleaved peptides were reconstituted in 0.1% TFA and separated by RP-HPLC on a Jupiter C18 
analytical col- umn using a linear gradient of 80% MeCN in 0.1% TFA at a flow rate of 1 ml-min−1. 
Molecular masses of the separated peptide fragments were determined by ESI-MS and their AA 
sequences determined by N-terminal sequencing. The complete AA sequence of fulditoxin was 
determined by alignment of the sequences of the CNBr-cleaved peptides. 
 
2.5 Size-exclusion chromatography for determination of oligomeric states of fulditoxin 
 
The oligomeric states of fulditoxin (0.15–1.5 μM) were determined by analytical size-exclusion 
chromatography using a Superdex 75 column (1 × 30 cm) equilibrated with 50 mM of Tris–HCl 
buffer, pH 7.4, in the absence and presence of 8-M urea. Size-exclusion 8hromatogram- phy was 
carried out on an ÄKTA purifier system at a flow rate of 0.6 ml-min−1. Columns were calibrated 
with BSA (66 kDa), carbonic anhydrase (29 kDa), cytochrome C (12.9 kDa), aprotinin (6.5 kDa), 
and blue dextran (200 kDa) as molecular mass markers. Native proteins as well as protein samples 
in 8-M urea were loaded separately onto the column. 
 
2.6 Chemical synthesis of fulditoxin 
 
Using established protocols (Dawson, Muir, Clark-Lewis, & Kent, 1994; Schnolzer, Alewood, 
Jones, Alewood, & Kent, 1992), the C-ter- minal 42-63 fragment (sequence 
CHEGAYNVCCSTDLCNKSSTSG) of fulditoxin was assembled on a Symphony (Protein 
Technologies Inc.) automated peptide synthesizer on an Fmoc (9- fluorenylmethoxycarbonyl)–Gly–
9 
 
Wang polystyrene resin (loading 0.37 mmol-g−1) on a 0.1-mmol scale. Fmoc deprotections were 
achieved using 30% piperidine/N,N-dimethylformamide (DMF; 1 × 1.5 min, then 1 × 4 min). 
Couplings were performed in DMF using 5 equivalents of Fmoc-AA/2-(1H-benzotriazol-1-yl)-
1,1,3,3- tetramethyluronium hexafluorophosphate (HBTU)/(N,N- diisopropylethylamine) DIEA 
(1:1:1) relative to resin loading for 2 × 20 min. AA side chains were protected as Asn (Trityl [Trt]), 
Asp (t- Butyl ester [OtBu]), Cys (Trt), Glu (OtBu), His (Trt), Lys (tert- butoxycarbonyl [Boc]), Ser 
(tertbutyl [tBu]), Thr (tBu), and Tyr (tBu). Cleavage from the resin and removal of side-chain 
protecting groups was achieved by treatment with 95% TFA/2.5% triisopropylsilane (TIPS)/2.5% 
water at room temperature for 2 hr. After most of the cleavage solution was evaporated under a 
stream of nitrogen gas, the product was precipitated and washed with cold diethyl ether (Et2O) and 
lyophilized from 50% MeCN/0.1% TFA/water. The crude product was purified by preparative 
HPLC. Mass of the purified product was determined by ESI-MS (described below). 
The N-terminal 1-41-thioester fragment of fulditoxin (sequence 
LKCYSSRTETMTCPEGEDKCEKYAVGLMHGSFFFIYTCTSKCOSR) was assembled using 
manual Boc protocols on a 0.25-mmol scale. Boc deprotections were achieved using TFA (2 × 1 
min). Couplings were performed in DMF using four equivalents of Boc-AA/ HBTU/DIEA (8:8:11) 
relative to resin loading for a minimum of 10 min. AA side chains were protected as Asp 
(Cyclohexyl ester [OcHxl]), Arg (4-toluenesulfonyl [Tos]), Cys (4-methylbenzyl [Meb]), Glu 
(OcHxl), His (Benzyloxymethyl [Bom]), Lys (2- chlorobenzyloxycarbonyl [2-ClZ]), Ser (benzyl 
[Bzl]), Thr (Bzl), and Tyr (2-bromobenzyloxycarbonyl [2-BrZ]). S-trityl-3-mercaptopropionic acid 
was coupled to Arg (Tos)-4-(oxymethyl) phenylacetamidomethyl (OCH2-PAM) polystyrene resin 
(loading 0.56 mmol·g−1) then the S-trityl group removed with 2 × 1 min treatments of 5% 
TIPS/TFA. The first AA of the sequence (Lys) was coupled to the resultant free thiol to form the 
thioester. Cleavage from the resin and removal of side- chain protecting groups was achieved by 
treatment with anhydrous hydrogen fluoride (HF)/p-cresol/H-Cys-Oet at 0o C for 1 hr. After 
evaporation of HF, the product was precipitated and washed with cold Et2O and lyophilized from 
50% MeCN/0.1% TFA/water. The crude product was purified by preparative HPLC and its mass 
deter- mined by ESI-MS (described below). 
Both fragments of fulditoxin were purified by RP-HPLC using solvents, 0.05% TFA/water 
as solution A and 90% MeCN/0.043% TFA/water as solution B. Analytical HPLC  was performed 
on a Shimadzu LC20AT system using a Thermo Hypersil GOLD 2.1 × 100 mm C18 column heated 
at 40o C with flow rate of 0.3  ml•min−1.  A  gradient  of  10  to  55%  B  over  30  min  was  used, 
with  detection  at  214  nm.  Preparative HPLC was performed on a Vydac 218TP1022 column (22 
× 250 mm) running at a flow rate of 16 ml•min−1 using a gradient of 10 to 50% B over 40 min. MS 




2.6.1 Native chemical ligation 
 
Purified 1-41-thioester (22 mg) and 42-63 (11 mg) fragments were combined and stirred in a 
solution containing 6-M guanidine hydro- chloride (GnHCl)/0.2-M sodium phosphate/20-mM tris 
(2- carboxyethyl) phosphine (TCEP)/50-mM MPAA (pH 7.0, 2.5 ml) for 16 hr at room temperature 
under an argon atmosphere; 1-63 octathiol fulditoxin was isolated by preparative HPLC (8 mg) and 
its mass determined by ESI-MS. 
 
2.6.2 Oxidative folding 
 
Purified reduced peptide (8 mg), reduced GSH (100 equivalent), and oxidized GSH (10 
equivalent) were dissolved in 6-M GnHCl (8 ml) then added to a solution of 1.55-M GnHCl/0.37-M 
ammonium acetate (pH 8.0, 71 ml) and stirred at 4o C with exposure to air for 48 hr. The 
predominant product was isolated by preparative HPLC (2 mg) and its mass determined by ESI-
MS. Analytical HPLC was carried out to compare the synthetic fulditoxin (sFulditoxin) with 
venom-purified native protein, nFulditoxin. 
 
2.7 Screening of fulditoxin action on isolated tissues in organ bath studies 
 
Isolated tissue experiments were conducted as described previously (Nirthanan, Gao, et al., 
2002; Nirthanan, Charpantier, et al., 2003; Pawlak et al., 2009; Roy et al., 2010) using a 
conventional organ bath (6 ml) containing physiological Krebs–Henseleit buffer of the following 
composition (in mM): 118-mM NaCl, 4.8 KCl, 1.2 KH2PO4, 2.5 CaCl2, 2.4 MgSO4, 25 NaHCO3, 
and 11 D-(+) glucose), pH 7.4. Organ bath chambers were continuously aerated with carbogen (5% 
carbon dioxide in oxygen) and maintained at 37o C throughout the experi- ment. The resting tension 
of the isolated tissues was maintained between 1- and 2-g tension, and the tissues were allowed to 
equili- brate for 30–45 min before the start of an experiment. Electrical field stimulation was carried 
out through platinum ring electrodes using a Grass stimulator S88 (Grass instruments, West 
Warwick, Rhode Island, USA). The magnitude of the contractile responses was mea- sured in gram 
tension. Data were continuously recorded on a PowerLab LabChart 6 data acquisition system using 
a force displacement transducer (Model MLT0201; ADInstruments, Bella Vista, NSW, Australia).  
 




The chick biventer cervicis muscle (CBCM) nerve-skeletal muscle preparation (Ginsborg & 
Warriner, 1960) was isolated from 3- to 5- day-old chicks and mounted in the organ bath chamber 
under similar experimental conditions as described above. Motor responses of the muscle were 
evoked by stimulating the motor nerve supramaximally by electrical field stimulation (7–10 V, 0.1 
ms, 0.2 Hz). Submaximal contractures to exogenously applied ACh (200 μM for 30 s), carbachol 
(CCh; 20 μM for 90 s), and KCl (30 mM for 60 s) were obtained in the absence of electrical field 
stimulation, prior to the addition of the toxin, and after complete blockade of nerve-evoked twitch 
responses in the muscle. The effect of crude MFV (1–100 μg-ml−1) and fulditoxin (5–500 nM) on 
nerve-evoked twitch responses of the CBCM was studied. The neuromuscular blockade produced 
by nFulditoxin was compared with that produced by EbTx-b (0.01–1 μM) and α-BgTx (0.001–1 
μM). The neuromuscular blockade was expressed as a percentage of the original twitch height, after 
30 min of exposure of the CBCM to either crude MFV or toxins. The recovery of the CBCM from 
complete neuromuscular blockade produced by crude MFV or toxins was assessed by washing out 
the toxin by bath overflow (16  ml-min−1) for the first 5 min followed by a slow drip-wash at a flow 
rate of ~8 ml-min−1 with fresh Krebs solution until maximal recovery. Three independent 
experiments were conducted for each concentration of toxin tested. 
 
2.8 Electrophysiological studies on native and sFulditoxin 
 
2.8.1 Electrophysiological studies on nFulditoxin 
 
Functional characterization of nFulditoxin was carried out via electro- physiological recordings on 
nAChRs expressed in Xenopus oocytes using an automated two-electrode voltage clamp (TEVC) 
system (Gen- eClamp Amplifier, Axon Instruments, Foster City, CA, USA) as described previously 
(Nirthanan, Charpantier, et al., 2002; Roy et al., 2010). The isolation, preparation, and injection of 
Xenopus oocytes were carried out as described previously and all experiments conformed to the 
Geneva canton rules on animal experimentation (accreditation number G171/3551; Hogg, 
Bandelier, Benoit, Dosch, & Bertrand, 2008). Oocytes were injected intra-nuclearly with expres- 
sion vectors containing the various cDNAs (2 ng) that encode for the different nAChR subunits 
using a Roboinject Automatic Injection System (Multi Channel Systems, Reutlingen, Germany) and 
maintained in 96-well plate at 18o C in filtered Barth solution containing NaCl (88 mM), KCl (1 
mM), NaHCO3 (2.4 mM), HEPES (10 mM, pH 7.5), MgSO4·7H2O (0.82 mM), Ca (NO3)2·4H2O 
(0.33 mM), CaCl2·6H2O (0.41 mM), at pH 7.4, and supplemented with 20 μg·ml−1 of kanamycin, 
100 U·ml−1 of penicillin, and 100 μg·ml−1 of streptomycin. TEVC recordings were made 2 to 3 days 
after injection. The oocytes were clamped at −100 mV and perfused with OR2 (oocyte Ringer) 
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medium containing (in mM) NaCl (82.5), KCl (2.5), MgCl2 (1.0), CaCl2 (2.5), HEPES (5.0), and 20 
μg·ml−1 of BSA, at pH 7.4, during recordings. Atropine (0.5 μM) was added to all solutions to 
block all activity attributed to muscarinic AChRs. ACh and nFulditoxin were prepared fresh in OR2 
solution and applied to the bath by gravity-driven perfusion. Control responses were recorded 
before toxin exposure and toxin incubation were carried out in the recording chamber between 3 
and 5 min with agitation. All recordings were performed with a TEVC automated robot system. The 
data were digitized and analysed offline using MATLAB (Mathworks, Natick, MA, USA; 
RRID:SCR_001622). 
 
2.8.2 Electrophysiological studies on sFulditoxin 
 
Independent of the experiments described above, functional characterization of sFulditoxin at 
receptor level was carried out using TEVC electrophysiology as described previously (Hassan-
Puttaswamy, Adams, & Kini, 2015). Stage V–VI oocytes were harvested from mature female 
Xenopus laevis under anaesthesia with 0.1% Tricaine as approved by the RMIT Animal Ethics 
Committee (Protocol # 1222, 1223). cRNA encoding for nAChR subunits were prepared and micro- 
injected into oocytes for nAChR expression. Briefly, cDNA encoding the human α3, α4, α9, α10, 
α7, β2, and β4 subunits, and rodent α1, β1, γ, δ, and ε subunits of nAChRs were sub-cloned into the 
oocyte expression vector pT7Ts and used for cRNA preparation using the mMESSAGE 
mMACHINE kit (Ambion®, Life Technologies Australia Pty. Ltd., Mulgrave, VIC, Australia); 25-
ng cRNA was microinjected into oocytes, at α:β ratio of 1:1 for the human heteromeric neuronal 
nAChR subtypes and α1:β1:δ:ε ratio of 2:1:1:1 for the rat muscle receptor. The oocytes were kept at 
18oC in ND96 buffer (96-mM NaCl, 2-mM KCl, 1-mM MgCl2, and 5-mM HEPES, pH 7.4) 
supplemented with 50 mg·L−1 of gentamicin and 100 units/μg·ml−1 of penicillin–streptomycin for 2 
to 5 days before recordings were undertaken. The oocytes were voltage clamped (virtual ground 
circuit) using a GeneClamp 500B amplifier (Molecular Devices, Sunnyvale, CA, USA). Voltage 
recording and current-injecting electrodes were pulled from borosilicate glass capillaries (GC150T-
7.5, Harvard Apparatus Ltd., Holliston, MA, USA) and filled with 3-M KCl to have resistances of 
0.3–1.5 MΩ. 
 
All TEVC recordings were done manually, at room temperature (20–23oC), using a bath 
solution of ND96. The oocytes were continuously perfused at a flow rate of 2 ml-min−1 with ND96 
buffer during recordings, with toxin incubated for 5 min before ACh was added. The concentration 
of ACh, calculated to be the EC50 concentration for the respective nAChR subtype, was applied for 
2 s at 2 ml·min−1, with 5-min washout periods between applications. Oocytes were volt- age 
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clamped at a holding potential of −80 mV for nAChRs. Data were filtered at 100 Hz and sampled at 
500 Hz. 
 
2.9 Data analyses 
 
In screening of fulditoxin on various nAChR subtypes, concentration response curves for 
antagonists were fitted by unweighted non-linear regression to the logistic equation: 
Y = bottom+(top – bottom)/(1+10 ^((Log IC50 – X) * Hill Slope)), where Y is the 
normalized response, X is the antagonist concentration, top and bottom are maximal and minimal 
normalized responses, respectively, and IC50 is the antagonist concentration giving 50% inhi- bition 
of the maximal response. 
EC50 shift of concentration–response plots were used to deter- mine the competitive or non-
competitive nature of the antagonist. The EC50 shift concentration–response plot (Arunlakshana & 
Schild, 1959) was plotted using the equation: 
 
EC50 = 10^Log EC50; 
 
Antag = 1 + (B/(10^ (− 1*pA2)))^Schild Slope; 
 
LogEC = Log (EC50*Antag); 
 
Y = bottom+(top – bottom)/(1+10 ^((Log EC – X) * Hill Slope)), where EC50 is the concentration 
of agonist that gives half maximal response; pA2 is the negative logarithm of the concentration of 
antagonist needed to shift the concentration–response curve by a factor of 2; Hill slope describes the 
steepness of the family of curves; Schild slope quantifies how well the shifts correspond to the 
prediction of competitive interaction and if the action is competitive, the Schild slope will equal 1.0, 
and top and bottom are plateaus in the units of the Y axis. Each data point represents the average ± 
SEM of three independent experiments. Computation was done using GraphPad Prism 6.03 (Gra- 
phPad software, Inc., La Jolla, CA, USA; RRID:SCR_002798). 
The data and statistical analysis in this study comply with the recommendations of the 
British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis et 
al., 2018). Given the limitations in the availability of fulditoxin due to its ultra-low yield in venom 
(<0.2%), and complexity in its chemical synthesis, statistical analyses have not been performed 
because fewer than five independent experiments were performed during the course of our studies. 
The pharmacology studies were not blinded as there was no expected outcome of screening 
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fulditoxin across nAChR subtypes for activity and determining the concentration–response 
relationships. 
 
2.10 Crystal structure determination of nFulditoxin 
 
Crystallization screens were performed using Hampton Research Crystal Screen I and II by 
hanging-drop vapour diffusion method in the mosquito crystallization robot. Initial hits were 
obtained from the condition containing 0.2-M zinc acetate dihydrate, 0.1-M sodium cacodylate 
trihydrate, pH 6.5, 18% w/v polyethylene glycol 8000. The identified initial condition was further 
optimized using grid screen, which was further optimized by grid screening. The complete diffrac- 
tion data from nFulditoxin crystals were collected at Beamline X6A of the National Synchrotron 
Light source. The crystals diffracted up to 1.95-Å resolution (Table 1). The data sets were processed 
and scaled using the program HKL2000 (Otwinowski & Minor, 1997). The Mat- thews coefficient 
was calculated as 2.18 Å3/Da (Matthews, 1968) corresponding to a solvent content of 44%. The 
structure was solved by the molecular replacement method using the program Phaser from the 
Phenix suite (McCoy et al., 2007; Zwart et al., 2008; RRID: SCR_014224) with β-cardiotoxin 
(PDB ID 3PLC) as the search model. The initial model was refined using Phenix-refine followed by 
model building using the Phenix AutoBuild program (Adams et al., 2004). The missing residues 
were manually built using the Coot program (Emsley & Cowtan, 2004; RRID:SCR_014222), 
followed by refinement with Phenix-refine (Adams et al., 2002). No non-crystallographic symmetry 
restrain was used in the final refinement cycle. Finally, 141 well-defined water molecules were 
















Table 1 | Crystallographic data and refinement statistics for fulditoxin 
Data collection   
Unit cell parameters (Å) a = b = 58.8, c = 70.57  
Space group P4212 
Resolution range (Å) 50-1.95 (1.98 - 1.95) 
Wavelength(Å) 0.97640 
Observed reflections 130267 
Unique reflections 9570 
Completeness (%) 99.9 (100) 
Overall I/σ(I) 10.8 
Redundancy 13.6 (13.7) 
RSym (%)
 a
 0.08 (0.42) 
Refinement and quality   
Resolution range (Å) 30 - 1.95 






rmsd bond length (Å) 0.007 










Most Favoured regions (%)  
Additionally allowed regions 
(%)  






Disallowed regions (%) 0 
a Rsym = |Ii -<I>|/ |Ii| where Ii is the intensity of the ith measurement, and <I> is the mean intensity 
for that reflection.        
b Rwork = | Fobs - Fcalc|/ |Fobs| where Fcalc and Fobs are the calculated and observed structure factor 
amplitudes, respectively.   




2.11 Dynamic light scattering 
 
The  apparent  hydrodynamic  radii  of  fulditoxin  (5  mg·ml−1)  in  the absence and presence 
of Zn2+ (3–30 μM) were examined by Protein Solutions DynaPro-99-E-50 Dynamic Light 




Lyophilized MFV was purchased from Medtoxin Venom Laboratories (DeLand, FL, USA). 
α-BgTx and EbTx-b were purchased from Latoxan (Valence, France). Superdex 30 Hiload 
(16/60), Superdex 75 (1 × 30 cm), Jupiter C18 preparative (5 μm, 300 Å, 21.2 × 250 mm), 
semi-preparative (5 μm, 300 Å, 10 × 250 mm), and analytical (5 μm, 300 Å, 4.6 × 250 mm) 
columns were purchased from GE Healthcare (Little Chalfont, UK). The following reagents 
and chemicals used for purification of MFV were from the sources indi- cated: reagents for 
N-terminal sequencing by Edman degradation (Applied Biosystems, Foster City, California, 
USA), potassium chloride (KCl), acetonitrile (MeCN), and trifluoroacetic acid (TFA; Merck 
KGaA, Darmstadt, Germany). Crystal screening solution and accessories were purchased 
from Hampton Research (Aliso Viejo, California, USA). All other chemicals were purchased 
from Sigma-Aldrich (St Louis, MO, USA). All the reagents used were of the highest purity 
grade. Water was purified using a MilliQ system (MilliPore, Billerica, MA, USA). 
 
2.13 Data deposition 
 
The coordinates and structure factors of fulditoxin are deposited in the Protein Data Bank 
(www.pdb.org; RRID:SCR_006555) with the code 4RUD. 
 
2.14 Nomenclature of targets and ligands 
 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 





3 RESULTS  
3.1 Bioassay-guided purification of fulditoxin from Micrurus fulvius venom 
 
Organ bath experiments with the isolated chick biventer cervicis nerve-skeletal muscle 
preparation (CBCM; Ginsborg & Warriner, 1960) were used as a screening bioassay to 
undertake two-step HPLC chromatography of MFV to isolate and purify the neurotoxic 
compo- nents. Crude MFV was first fractionated based on MW, by size-exclu- sion 
chromatography (Figure 1a), and fractions which elicited neuromuscular blocking activity 
(indicated by horizontal black bar) were pooled and sub-fractionated by RP-HPLC (Figure 
1b). Peak 3c (indicated by an arrow), which elicited potent neuromuscular block- ade, was 
further purified to homogeneity by RP-HPLC using a shallow gradient (Figure 1c). The 
molecular mass and homogeneity of fulditoxin was determined by ESI-MS to be 6947.4 ± 0.6 
Da (Figure 1d). Capillary electrophoresis confirmed the homogeneity of purified fulditoxin, 
revealing a single protein peak in the electropherogram indicating the absence of 
contaminants (Figure 1e). 
 
3.2 Fulditoxin forms a non-covalent dimer in solution 
 
During size-exclusion chromatography, it was observed that fulditoxin was contained in peak 
3 (Figure 1a), in contrast to most 3FTxs which eluted later, as observed in our previous 
studies (Nirthanan, Charpantier, et al., 2002; Rajagopalan et al., 2007). This suggested that 
fulditoxin may exist in dimeric form. In analytical size-exclusion chro- matography, 
fulditoxin eluted as a single peak corresponding to a rela- tive molecular mass of 3.88 kDa in 
the presence of 8-M urea, compared to as a single peak corresponding to a mass of 11.56 kDa 
in the absence of urea (Figure 1f). Hence, this purified toxin was named “fulditoxin”—













Figure 1 Isolation and purification of fulditoxin from crude Micrurus fulvius fulvius 
venom. Multi-step HPLC purification of M. fulvius venom, determination of fulditoxin's MW 
by MS, and determination of its purity by capillary electrophoresis. (A) Size-exclusion 
chromatography of crude MFV (50 mg·ml−1) on a Superdex 30 HiLoad (16/60) column. The 
column was pre-equilibrated with Tris–HCl buffer (50 mM), pH 7.4. Proteins were eluted at a 
flow rate of 1.0 ml·min−1 using the same buffer. Protein elution was monitored at 280 nm. 
The fractions indicated by a horizontal black bar corresponding to peak 3 were pooled and 
subjected to RP-HPLC. (B) RP-HPLC profile of size-exclusion chromatography peak 3 on a 
Jupiter C18 preparative column (5 μm, 300 Å, 21.2 × 250 mm) using a linear gradient (25–
50% over 108 min; dotted line) of buffer B (80% ACN in 0.1% TFA) at a flow rate of 5 
ml·min−1. Protein elution was monitored at 215 nm. The peak indicated by an arrow 
corresponding to peak 3c was rechromatographed on a shallower gradient. (C) 
Rechromatogram of peak 3c obtained by RP-HPLC on a semi-preparative column (5 μm, 300 
Å, 10 × 250 mm) using a shallow gradient (25–45% over 80 min; dotted line) of buffer B 
(80% ACN in 0.1% TFA) at a flow rate of 2 ml·min−1. Protein elution was monitored at 215 
nm. The resulting protein peak indicated by the arrow was named fulditoxin. (D) ESI-MS 
profile of fulditoxin. The spectrum shows a series of multiply charged ions with mass/charge 
(m/z) ratios ranging from +4 to +6 charges. Inset, reconstructed mass spectrum of fulditoxin 
corresponding to a single homogeneous protein with MW of 6947.4 Da; CPS = counts s−1; 
a.m.u = atomic mass units. (E) Capillary electrophoresis of fulditoxin shows a single peak 
supporting homogeneity. (F) Analytical size-exclusion chromatography profile of fulditoxin; 
1.5-μM fulditoxin was loaded onto a Superdex 75 column (1 × 30 cm) equilibrated with 50-




M urea respectively. (G) MW determination on size-exclusion column. Column calibration 
was done using BSA (ALB; 66 kDa), carbonic anhydrase (CA; 29 kDa), cytochrome c (CYC; 
12.9 kDa), aprotinin (AP; 6.5 kDa), and blue dextran (200 kDa) as molecular mass markers 
 
3.3 Amino acid sequence of fulditoxin 
 
N-terminal sequencing of fulditoxin was carried out by automated Edman degradation. The 
first 40 AA residues of the toxin were identified by direct sequencing of the native toxin, and 
the remaining residues were determined by sequencing of overlapping fragments of 
chemically-cleaved fulditoxin (see Figure S2). The calculated mass of 6946.85 Da of the full-
length fulditoxin sequence agreed with its experimentally determined molecular mass (6947.4 
± 0.6 Da). Basic Local Alignment Sequence Tool (BLAST) search (Altschul et al., 1997; 
RRID:SCR_004870) showed that fulditoxin shares the highest identity (68–99%) with 
sequences of Micrurus 3FTxs identified by trans- criptomic analyses (Correa-Netto et al., 
2011; Margres, Aronow, Loyacano, & Rokyta, 2013; Rey-Suarez et al., 2012; Vergara et al., 
2014; Figure 2a). 
Multiple sequence alignment of fulditoxin with other classes of 3FTxs, including α-
neurotoxins, cardiotoxins, cytotoxins, and AChE inhibitors, showed little sequence 
similarities (Figure 2b). Fulditoxin shared only ~20% to 30% sequence identity with other 
monomeric short-chain α-3FNTxs (Figure 2c), dimeric α-3FNTxs (Figure 2d), and α-3FNTxs 
which are reversible in their neuromuscular blocking action (Figure 2e), a pharmacological 
characteristic shared by fulditoxin. Notably, none of the conserved functional AA residues 
experimentally shown to be critical for α-3FNTxs to inhibit nAChRs are present in the 

















Fulditoxin         M. f. fulvius       -     LKCYSSRT------ETMTCPEGEDK-CEKYAVGL---MHGSFFFIYTCTSKCHEGAYN----VCCSTDLCNKSSTSG- 63    
Candoxin           B. candidus      P81783   MKCKICNFDTCRAGELKVCASGEKY-CFKESWR----EARGTRIERGCAATCPKGSVYGLYVLCCTTDDCN------- 66 26   
Haditoxin          O. hannah        A8N286   TKCYNHQSTT-PETTEI-CP-DSGYFCYKSSWID----GREGRIERGCTFTCPELTPNGKYVYCCRRDKCNQ------ 65 26  
LSIII              P. semifasciata  P01379   RECYLNP-----HDTQT-CPSGQEI-CYVKSWCNAWCSSRGKVLEFGCAATCPS-VNTGTEIKCCSADKCNTYP---- 66 26  
CM10               N. annulifera    P01420   MICYKQQSLQFPITTV--CPGEKN--CYKKQWSG----HRGTIIERGCG--CPSVKKG-IEINCCTTDKCNR------ 61 19 
CM12               N. annulifera    P01421   MICYKQRSLQFPITTV--CPGEKN--CYKKQWSG----HRGTIIERGCG--CPSVKKG-IEINCCTTDKCNR------ 61 24 
S5C10              D. j. Kaimosae   P01419   RICYNHQSNTP-ATTKS-CV-ENS--CYKSIWAD----HRGTIIKRGCG--CPRVKS---KIKCCKSDNCNL------ 58  8 
Fasciatoxin        B. fasciatus     P14534   LKCHKAQF---PNIETQ-CK-WQT-LCFQRDVKP---HPSSMIVLRGCTSSCGKGAM------CCATDLCNGPSTPST 63 28 
Pseudonajatoxin b  P. textilis      P13495   RTCFITPD----VKSKP-CPPGQEV-CYTETWCDGFCGIRGKRVELGCAATCPTPKKTGIDIQCCSTDDCNTFPLRP- 71 25 
 
 
   
A   Closely-related Micrurus three-finger toxins 
  









C   Short-chain three-finger α-neurotoxins 
B   Three-finger toxins     
D  Dimeric three-finger neurotoxins 





Fulditoxin     M. f. fulvius             LKCYSSRT----ETMTCPEGEDKCEKYAVGLMHGSFFFIYTCTSKCHEGAYNV---CCSTDLCNKSSTSG 63         
Erabutoxin-a   L. semifasciata  P60775   RICFNHQSSQPQTTKTCSPGESSCYNK-QWSDFRGTIIERGCG--CPTVKPGIKLSCCESEVCNN----- 62  20 
Erabutoxin-b   L. semifasciata  Q90VW1   RICFNHQSSQPQTTKTCSPGESSCYHK-QWSDFRGTIIERGCG--CPTVKPGIKLSCCESEVCNN----- 62  20    
Toxin-α        N. nigricollis   1NEA     LECHNQQSSQPPTTKTC-PGETNCYKK-VWRDHRGTIIERGCG--CPTVKPGIKLNCCTTDKCNN----- 61  24   
α-Neurotoxin   D. polylepis     1NTX     RICYNHQSTTRATTKSC--EENSCYKK-YWRDHRGTIIERGCG--CPKVKPGVGIHCCQSDKCNY----- 60  23   
   
E   Reversible three-finger neurotoxins 






Fulditoxin M fulvius                   LKCYSSR-TETMTCPEGEDKCEKYAVGL-MHGSFFFIYTCTSKCHEGAYNVCCSTDLCNKSSTSG 63 
3FTx-3b M fulvius U3EPL2     LKCYSSR-TETMTCPEGEDKCEKYAAGL-MHGSFFFIYTCTSKCHEGAYNVCCSTDLCNKSSTSG 63 99 
3FTx-9c  M fulvius A0A0F7Z039 LKCYSSR-TETMTCPEGEDKCEKYAVGL-MHGSFFFIYTCASKCHEGAYNVCCSTDLCNKSSTSG 63 98 
3FTx-17c M tener A0A194ATC3 LKCYSSR-TETMTCPEGKDKCEKYAAGL-MPGSFFFIYTCTSKCHEGAYNVCCSTDLCNKSSTSG 63 98 
3FTx-17a M tener A0A194ARD0 LKCYSSR-TETMTCPEGKDKCEKYAVGL-MPGSFFFIYTCTSKCHEGAYNVCCSTDLCNKSSTSG 63 96 
3FTx-17f M tener A0A194ASE5 LKCYSSR-TETMTCPEGKDKCEKYAVGL-MPGSFFFIYTCTSKCHEGAYNVCCSTDLCNESSTSG 63 95 
3FTx-4a M tener A0A194ARC1 LKCYSSR-TETMTCPEGKDKCEKYAVGL-MPGTWSYHWDCASTCHRGKYNVCCSTDLCNK----- 58 82 
3FTx-16d M tener A0A194ARK4 LKCYSSR-TETMTCPEGKDKCEKYAVGL-MPGTWSYHWGCASTCHRGKYNVCCSTDLCNK----- 58 82 
3FTx-4b M tener A0A194ATB5 LKCYSSR-TETMTCPEGKDKCEKYAGGL-MPGTWSYHLDCASTCHRGKYNVCCSTDLCNK----- 58 82 
3FTx-16c M tener A0A194ASF2 LKCYSSR-TETMTCPEGKDKCEKYAVGL-MPGTWSYHRGCVSTCHRGKYNVCCSTDLCNK----- 58 82 
3FTx-16a M tener A0A194APH5 LKCYSSR-TETMTCPEGKDKCEKYAVGL-MPGTWSYHRGCASTCHRGKYNVCCSTDLCNK----- 58 82 
3FTx-1 M corallinus C6JUP1  LICYNTM-MQKVTCPEGKDKCEKYAVPV-MRGKFYFSYQCTSKCHEGAYDVCCSTDLCNKSSTSG 63 79 
3FTx-LC M laticorralis A0A0H4BKI7 LICYSSK-SDTMTCPEGQNKCEKYAVPL-MQGRWFYSYECTSACHRGPYNVCCSTDLCNK----- 58 78 
3FTx-A2 M laticorralis K9MCX0   LVCYVSG-AWQKTCPEGQNKCEKYAVGT-MHGSWIYLRGCASTCHEGPYNVCCSTDLCNK----- 58 74 
3FTx-LD M laticorralis A0A0H4BFP9 LVCYVSG-AWQKTCPEGQNKCEKYAVGT-MHGSWKYLRGCASTCHEGPYNVCCSTDLCNE----- 58 73 
MALT0063C M altirostris F5CPE2     LICYVSEYGAKMTCPEGKTLCEKYAVPL-MQGHFYFAWRCTSTCKAGAYNICCSTDLCNKIP--- 60 71 
MALT0059C M altirostris F5CPE0     LICYVTRDGKTATCPPGQ-KCEKYAVSASHTGHWFHRWHCTSTCHEGPYNVCCSTDFCNR----- 58 68 
                                  
 
 
Loop I Loop II Loop III
Fulditoxin      M. f. fulvius       -      ---------LKCYSS---RTET----MTCPEGEDKCEKYAVGLMHG---SFFFIYTCTSKCHEGAY----NVCCST-DLCNKSSTSG-- 63               
Erabutoxin a    L. semifasciata   P60775   ---------RICFNH--QSSQPQTTK-TCSPGESSCYNKQWSDFRG----TIIERGCG--CPTVKPGIK-LSCCES-EVCNN------- 62  20 
α-bungarotoxin  B. multicinctus   P01378   ---------IVCHTT---ATSP-ISAVTCPPGENLCYRKMWCDAFCSSRGKVVELGCAATCPSKKP-YEEVTCCST-DKCNPHPKQRPG 74  26 
κ-bungarotoxin  B. multicinctus   P01398   ---------RTCLIS---PSS---TPQTCPNGQDICFLKAQCDKFCSIRGPVIEQGCVATCPQFRSNYRSLLCCTT-DNCN-H------ 66  23 
Candoxin        B. candidus       P81783   ---------MKCKICNFDTCRAGELKV-CASGEKYCFKESWREA----RGTRIERGCAATCPKGSVYGLYVLCCTT-DDCN-------- 66  26 
Denmotoxin      B. dendrophila    Q06ZW0   QAVGLPHGF--CIQCNRKTWSNCSIGHRCLPYHMTCYTLYKPDENG--EMKWAVKGCARMCPTAKS-GERVKCCTG-ASCNSD------ 77   7 
MT2             D. angusticeps    P18328   ---------LTCVTT---KSIGGVTTEDCPAGQNVCFKRWHYVTP---KNYDIIKGCAATCPKVDN-NDPIRCCGT-DKCND------- 65  25 
Cytotoxin 4     N. mossambica     P01452   ---------LKCN--KLIP-IAYK---TCPEGKNLCYKMMLASK----KMVPVKRGCINVCPKNSA-LVKYVCCST-DRCN-------- 60  28 
Mambin          D. j. Kaimosae    P28375   ---------RICYNHLGTKPPTTE---TCQ--EDSCYKNIWT-FD-----NIIRRGCG--CFTPRGDMPGPYCCES-DKCNL------- 59  10 
Toxin FS-2      D. p. polylepis   P01414   ---------RICYSHKASLPRATK---TCV--ENTCYKMFIRTHRQ----YISERGCG--CPTAMWPYQ-TECCKG-DRCNK------- 60  10 
Fasciculin-1    D. angusticeps    P0C1Y9   ---------TMCYSHTTTSRAILT---NCG--ENSCYRKSRRHPPK----MVLGRGCG--CP-PGDDYLEVKCCTSPDKCNY------- 61  22 
  
 
                                                                                            
Loop I Loop II Loop III
Name                          Organism            Accession                                                   Amino acid sequence % Id                      
Fulditoxin  M. f. fulvius      - -------LKCYSSRTETMT-------CPEGEDKCEKYAVGLMHGSF---FFIYTCTSKCHEGAYN----VCCSTDLCNKSSTSG-- 63
κ-bungarotoxin B. multicinctus  P01398  -------RTCLISPSSTPQT------CPNGQDICFLKAQCDKFCSIRGPVIEQGCVATCPQFRSNYRSLLCCTTDNCNH------- 66 28
α-cobratoxin    N. kaouthia          P01391 -------IRCFITPDITSKD------CPNG-HVCYTKTWCDAFCSIRGKRVDLGCAATCPTVKTG-VDIQCCSTDNCNPFPTRKRP 71 26
Haditoxin        O. hannah A8N286 -------TKCYNHQSTTPETTE---ICPDSGYFCYKSSWIDGREGR----IERGCTFTCPELTPNGKYVYCCRRDKCNQ------- 65 26
Irditoxin A      B. irregularis A0S864  QAVGPPYTLCFECNRMTSSDCSTALRC--YRGSCYTLYRPDENCELK--WAVKGCAETCPTAGPN-ERVKCCRSPRCNDD------ 75 17
Irditoxin B      B. irregularis A0S865      QAKGPPYTLCFECNRETCSNCFKDNRCPPYHRTCYTLYRPDGNGEMK--WAVKGCAKTCPTAQPG-ESVQCCNTPKCNDY------ 77 19
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Figure 2 Comparison of the amino acid sequence of fulditoxin with sequences other 
snake three-finger toxins. In all panels, the accession numbers and the source organism are 
indicated. Only the conserved cysteine residues within each groups are shaded in grey. The 
number of amino acid residues and the percentage identity (% Id) of the respective toxins 
with fulditoxin is indicated at the end. The disulfide linkages and segments contributing to 
the three loops are also shown. (A) The amino acid sequence of fulditoxin was subjected to 
Protein BLAST search for sequence homology with protein databases. The top 16 protein 
sequences that shared the highest sequence homology with fulditoxin are shown. Identical 
amino acid residues across all 17 sequences are shaded in grey. The amino acid residues that 
contribute to hydrogen bond formation (shaded in black) and hydrophobic interactions 
(underlined) in the dimeric interface of fulditoxin are highlighted across the sequences. (B) 
The sequence of fulditoxin as compared with the sequences of other 3FTxs, each representing 
a different subfamily: erabutoxin a, short-chain α-neurotoxin; α-bungarotoxin, long-chain α-
neurotoxin; κ-bungarotoxin, κ-neurotoxins; candoxin, elapid non-conventional three-finger α-
neurotoxin; denmotoxin, colubrid non-conventional three-finger α-neurotoxins; MT2, 
muscarinic three-finger toxin; cytotoxin 4, cardiotoxin; mambin, antagonist of cell-adhesion 
processes; Toxin FS-2, L-type calcium channel antagonist; and fasciculin-1, 
acetylcholinesterase inhibitor. (C) Comparison of the amino acid sequence of fulditoxin with 
the sequences of short-chain 3F-αNTxs. The conserved amino acid residues in short-chain 
3F-αNTxs deemed critical for the recognition and binding to muscle-type nAChRs are 
highlighted in black. (D) Comparison of the amino acid sequence of fulditoxin with the 
sequences of dimeric 3F-NTxs. The cysteine residues involved in the formation of 
intermolecular disulfide linkages are underlined in the sequences of the α-cobratoxin dimer 
and irditoxin A - irditoxin B dimer.  (E) Comparison of the amino acid sequence of fulditoxin 











3.4 Chemical synthesis of fulditoxin 
 
Solid-phase assembly of full-length fulditoxin (1-63) was initially attempted using 
automated Fmoc (9-fluorenylmethoxycarbonyl) chemistry. While the correct mass was 
observed in the crude product, it was not possible to efficiently separate it from 
accompanying impurities. It was therefore decided to synthesize the peptide fragments that 
could be subsequently assembled using native chemical ligation (Dawson, Muir, Clark-
Lewis, & Kent, 1994). The 1-41-thioester segment was synthesized as a single chain using 
Boc (tert- butyloxycarbonyl) chemistry and subsequently solubilized and purified (Alewood 
et al., 1997). ESI-MS of the purified product revealed a mass of 4937.2 Da. Likewise, the C-
terminal 42-63 fragment was synthe- sized and solubilized, and the purified product showed a 
mass of 2278.8 Da. Native chemical ligation of the 1-41-thioester and 42-63 fragments then 
proceeded efficiently to yield full-length linear fulditoxin 1-63 (Figure S3A–C). ESI-MS of 
the purified 1-63 octathiol fulditoxin revealed a mass of 6956.8 Da. Oxidative folding of the 
reduced peptide produced a single predominant isomer with expected mass of 6946.8 Da 
(Figure S3D,E). The isolated major product (sFulditoxin) was indistinguishable from 
nFulditoxin by analytical RP-HPLC (Figure S3F). 
 
3.5 Fulditoxin is a reversible postsynaptic neuromuscular blocker 
 
The effects of purified nFulditoxin (5–500 nM) on neuromuscular transmission were 
studied in ex vivo organ bath experiments using the CBCM. nFulditoxin produced time- and 
concentration-dependent blockade of nerve-evoked twitch responses in indirectly stimulated 
CBCM (IC50 = 27.8 nM; 95% CI [17.7, 43.1]; Figure 3a–c), based on the percentage of 
neuromuscular blockade observed after 30-min incubation with the toxin. The contractile 
responses of the CBCM to exogenously applied agonists ACh and CCh were also largely 
abolished in the presence of fulditoxin, whereas the KCl-induced contraction was unaffected, 
indicating a blockade of postsynaptic muscle nAChRs, with no pharmacological evidence of 
myotoxicity (Figures 3a and S4B). This was consistent with preliminary screening of crude 
MFV that also showed no evidence of myotoxicity in the CBCM (Figure S4A). The 
neurotoxic potency of nFulditoxin was comparable to α-BgTx (IC50 = 11.4 nM; 95% CI [7.9, 
16.2]) and EbTx-b (IC50 = 31.7 nM; 95% CI [21.8, 45.8]; Figure 3c). Thus, fulditoxin is 
among the most potent antagonists of ACh transmission in the CBCM (avian nAChR). In 
contrast, candoxin (Bungarus candidus) from the non-conventional class of α-3FNTxs 
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(Nirthanan, Charpantier, et al., 2002; Nirthanan, Charpantier, et al., 2003) showed weaker 
inhibition of the CBCM (IC50 = 1.6 μM; 95% CI [1.3, 2.0]; Figure S4C). 
The reversibility of the neuromuscular blockade produced by fulditoxin was evaluated 
through intermittent washing of the CBCM with fresh Krebs solution. Over 90% recovery of 
nerve-evoked twitch responses was attained within 30 min of tissue washing (Figure 3b), in 
contrast to α-BgTx and EbTx-b which are poorly reversible α-3FNTxs (Figure 3d). The 
reversibility of neuromuscular blockade produced by fulditoxin was also compared with 
candoxin (Figure 3d); and the time taken for 50% recovery from neuromuscular blockade 



















Figure 3 Reversible postsynaptic neuromuscular blockade produced by fulditoxin in the 
avian neuromuscular junction. Pharmacological characterization of native fulditoxin 
(nFulditoxin) on isolated nerve-muscle models in organ bath experiments. (A) Segment of 
tracing showing the blockade of nerve-evoked twitches of the chick biventer cervicis muscle 
(CBCM) produced by fulditoxin (0.5 μM). Contractions produced by exogenous ACh (200 
μM), carbachol (CCh; 20 μM), and KCl (30 mM) before and after incubation with 
nFulditoxin are also shown. (B) Segment of tracing showing the reversible blockade of nerve-
evoked twitches of the CBCM produced by nFulditoxin (0.5 μM). Upon 80% inhibition of 
the nerve-evoked twitch responses, the muscle was washed with fresh Krebs solution (washes 
lasting 30 s, at intervals of 1 min, for a period of 30 min) to remove the toxin from the bath 
chamber. In panels (A) and (B), the black horizontal bar indicates EFS (0.2 Hz, 0.1 ms and 7–
10 V) and the unfilled bar indicates the duration of the wash. (C) Concentration–response 
curves for the neuromuscular blockade produced by nFulditoxin, α-bungarotoxin and 
erabutoxin-b and candoxin. Neuromuscular blockade was calculated as the twitch height of 
the muscle after 30-min exposure to the respective toxin, expressed as a percentage of the 
control twitch responses of the muscle to supramaximal nerve stimulation. The IC50 values of 
nFulditoxin, α-bungarotoxin, erabutoxin-b, and candoxin on the CBCM are 27.8 nM (95% CI 
[17.7, 43.1]), 11.4 nM (95% CI [7.9, 16.2]), and 31.75 nM (95% CI [21.8, 45.8]) 







(D) Comparison of reversibility of neuromuscular blockade showing the time course of 
reversal of the neuromuscular blockade produced by nFulditoxin, α-bungarotoxin, 
erabutoxin-b, and candoxin. The recovery is calculated as a percentage of the control twitch 
responses. Each data point represents the mean ± SEM of three independent experiments 
 
3.6 Selectivity of fulditoxin for muscle and neuronal nAChR subtypes 
 
As nFulditoxin produced potent neuromuscular blockade in isolated nerve-muscle 
preparations, it was screened for its effects on human muscle (hα1β1δε) nAChRs expressed 
in Xenopus oocytes using TEVC electrophysiology. nFulditoxin produced partially (~65%) 
reversible, concentration-dependent inhibition of hα1β1δε nAChRs (IC50 = 2.56 μM; see 
Figure S5A,B). Thus, the affinity towards hα1β1δε nAChRs was ~100 times lower than that 
for avian muscle nAChRs. Additionally, nFulditoxin also produced reversible blockade of 
human neuronal α7 (hα7) nAChRs (IC50 = 6.57 μM; Figure S5C,D). Due to the scarcity of 
nFulditoxin, the highest concentration tested was 15 μM, which produced only 45% 
inhibition of ACh-evoked currents in hα7 nAChRs but was adequate to completely block 
hα1β1δε nAChRs. 
We then characterized the selectivity of sFulditoxin for seven different nAChR 
subtypes, namely, rodent adult muscle (rα1β1δε) and human neuronal hα7, hα9α10, hα4β2, 
hα4β4, hα3β2, and hα3β4 nAChRs (Figure 4a). sFulditoxin was selective for rα1β1δε (IC50 = 
2.6 μM; 95% CI [2.2, 3.1]) as well as hα4β2 (IC50 = 1.8 μM; 95% CI [1.6, 2.1]), hα7 (IC50 = 
7.0 μM; 95% [CI 5.8, 8.4]), and hα3β2 (IC50 = 12.6 μM; 95% CI [11.3, 13.9]) subtypes. It 
also weakly inhibited hα4β4 (IC50 not determined), but not the hα9α10 and hα3β4 nAChRs, 
even at 30 μM (Figure 4b,c). The nH of fulditoxin binding to rα1β1δε, hα4β2, hα7, and hα3β2 
receptors were −1.5, −1.1, −1.7, and −1.2 respectively, suggesting non-cooperative ligand–
receptor interaction (Prinz, 2010). Importantly, it was observed that sFulditoxin blocked 
rα1β1δε (IC50 = 2.6 μM) and hα7 (IC50 = 7.0 μM) subtypes with IC50 values similar to those 
for hα1β1δε (IC50 = 2.56 μM) and hα7 (IC50 = 6.57 μM), noting that the experiments with 
sFulditoxin and nFulditoxin were independently carried out in different laboratories. 






3.7 Fulditoxin competitively inhibits ACh binding to the ACh-binding pocket of muscle 
nAChRs 
 
To determine whether fulditoxin's low sequence identity with other α-3FNTxs (including the 
absence of canonical functional AA residues) would allow it to potentially bind at a different 
site at the nAChR (non-competitive allosteric antagonism) or exhibit a unique mode of 
interaction (competitive orthosteric antagonism), we analysed sFulditoxin's effects at rα1β1δε 
nAChRs activated by serial concentra- tions of ACh (Figure 4d). At concentrations of 3 and 
30 μM, fulditoxin shifted the agonist concentration–response curve to the right, with- out any 
change in the apparent maximum response (Figure 4e). Thus, fulditoxin acts as a competitive 







Figure 4 Activity of fulditoxin at nAChR subtypes expressed in Xenopus oocytes. TEVC 
electrophysiological characterization of synthetic fulditoxin (sFulditoxin) on nAChR 
subtypes expressed in Xenopus oocytes. (A) Superimposed representative ACh-evoked 
currents from Xenopus oocytes expressing rαβδε, hα7, hα9α10, hα3β2, hα4β4, hα4β2, and 
hα3β4 nAChRs in the absence (black trace) and presence of 30-μM sFulditoxin (red trace). 
For the nAChR subtypes indicated, r and h represent the species, rodent and human 
respectively. Whole-cell nAChR-mediated currents were activated by ACh at a concentration 
that represented the EC50 of ACh for the respective subtype expressed in the oocyte. (B) 
Histogram showing the effects of 30-μM sFulditoxin on relative ACh-evoked current 
amplitude mediated by rαβδε (n = 3), hα7 (n = 3), hα9α10 (n = 3), hα3β2 (n = 4), hα3β4 (n = 
3), hα4β2 (n = 3), and hα4β4 (n = 4) nAChRs. (C) Concentration–response curves of 
sFulditoxin inhibition of selective nAChR subtypes revealed the following IC50 values for the 
nAChR subtypes tested: hα7 = 7.0 μM (95% CI [5.8, 8.4]; n = 3), rαβδε = 2.6 μM (95% CI 
[2.2, 3.1]; n = 3), hα3β2 = 12.6 μM (95% CI [11.3, 13.9]; n = 4), and hα4β2 = 1.8 μM (95% 
CI [1.6, 2.1; n = 4). (D) TEVC electrophysiological characterization of sFulditoxin on rodent 
muscle αβδε nAChRs expressed in Xenopus oocytes showing competitive antagonism of 
ACh binding. Representative superimposed traces of responses to varying concentrations of 
ACh, with or without 3-μM sFulditoxin (top) or 30-μM sFulditoxin (bottom). (E) 
Concentration– response curves obtained from the traces of ACh- evoked responses, with or 
without sFulditoxin at 3 μM and 30 μM. Each data point is the mean ± SEM of three 
independent experiments 
 
3.8 Fulditoxin is a unique non-covalent dimer 
 
The crystal structure of fulditoxin was determined to 1.95-Å resolu- tion (Figure 5; Table 1). 
There were two molecules, each consisting of AA residues Leu1 to Lys58 (Figure 5a), 
forming a tight dimer in the asymmetric unit. Both monomers were well defined in the 
electron density map except for five C-terminal residues (Figure 5b). Each monomer of the 
asymmetric unit has the characteristic three-finger protein scaffold consisting of three β-
sheeted loops extending from a central core which is stabilized by four highly conserved 
disulfide bridges (Cys3-Cys20, Cys13-Cys38, Cys42-Cys50, and Cys51-56). Loop I is 
formed by two anti-parallel β-strands βA (Lys2-Tyr4) and βB (Thr10-Thr12), whereas loops 
II and III formed a three-stranded β-sheet, βC (Lys19 - Met28), βD (Ser31-Thr39), and βE 
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(Val49 - Cys51; Figure 5a). Both monomers were related by a twofold symme- try, and their 
superimposition yielded an RMSD of 0.623 Å for 58 Cα atoms (Figure 5d). A search for 
topologically similar proteins within the PDB database was performed with the program 
DALI (Holm & Sander, 1998), which showed similarity with several 3FTxs including 
neurotoxins and cardiotoxins (Table S1). Each monomer of fulditoxin is structurally similar 
to short-chain α-3FNTxs such as EbTx-a (PDB code 5EBX) and Naja nigricollis toxin-α 
(PDB code 1IQ9; Figure 5e), but loops I and III in fulditoxin are shorter, and loop II is 
orientated in the opposite direc- tion when compared to the corresponding loops in other 
short-chain α-3FNTxs. Fulditoxin also showed overall structural similarity with long 
neurotoxin-1 (PDB code 1YI5), but significant differences were observed in the length of 
loop I and orientation of loop II between long neurotoxin-1 and short-chain α-3FNTxs, EbTx-
b (PDB code 6EBX), and fulditoxin (Figure S6). 
 
3.9 Dimer interface comprised primarily of hydrophobic interactions 
 
Approximately 514-Å2 (~12% of the total) surface areas were involved in the dimerization as 
calculated by the Protein Interfaces, Surfaces and Assemblies server analysis (Krissinel & 
Henrick, 2007). There are 20 AA residues from both monomers involved in the dimerization; 
with close contacts between the monomers maintained by 29 hydro- phobic interactions and 
three hydrogen bonds (<3.2 Å; see Tables S2A,B and Figure 5b). These three hydrogen 
bonds were all side chain–side chain contacts, with two of them observed between Thr37 and 
His43 from both monomers. The hydrogen bonding con- tacts were observed between βE of 
monomer A and βD of monomer B and vice versa. The third hydrogen bond was observed 
between Ser40 of both monomers located in the loop which connects βD and βE (Table S2A; 
Figure 5b). These observations strongly suggest the existence of fulditoxin as a non-
covalently linked homodimer, which is consistent with analytical size-exclusion 














Figure 5 Overall structure of fulditoxin (PDB # 4RUD). X-ray crystallographic structure 
of fulditoxin. (A) Fulditoxin dimer. Monomer A and monomer B of fulditoxin are shown in 
blue and red respectively. The N- and C-termini are labelled as NH2 and COOH respectively. 
β-strands and loops I–III (I00–III') are labelled. Disulfide linkages are shown in yellow. (B) 
Dimeric interface of fulditoxin showing the hydrogen bonding interactions. Residues 
involved in the hydrogen bonding are labelled. All the hydrogen bonds are side chain-
mediated hydrogen bonds. (c) Hydrophobic interactions in the dimeric interface of fulditoxin. 
Residues involved in the hydrophobic interactions are labelled. (D) Superimposition of 
fulditoxin monomers [(A) in blue and (B) in red]. Both the monomers were related by a 
twofold symmetry and their superimposition yielded an RMSD of 0.6233 Å for 58 Cα atoms. 
The N- and C-termini are labelled as NH2 and COOH respectively. (E) Superimposition of 
fulditoxin monomer A with short-chain three- finger α-neurotoxins. Fulditoxin monomer A is 
shown in blue, erabutoxin-a in yellow (5EBX; RMSD 1.86 Å for 53 Cα atoms), erabutoxin-b 
in pink (3EBX; RMSD 1.87 Å for 53 Cα atoms), toxin- α in orange (1IQ9: RMSD 1.88 Å for 
53 Cα atoms), and neurotoxin-β in cyan (1NXB; RMSD 1.98 Å for 51 Cα atoms). Loops I to 
III are indicated. The PDB codes are given in parentheses 
 
3.10 Zinc-binding enables fulditoxin to form a tetrameric complex 
 
The crystal structure of fulditoxin, determined under conditions containing Zn2+, revealed 
two Zn2+ ions, each bound to four fulditoxin monomers arranged in a tetrahedral coordination 
geometry, resulting in the formation of a tetramer of dimers (Figure S7A). The tetrameric 
complex is formed by four dimeric fulditoxin molecules held together by two Zn2+, with each 
Zn2+ interacting with His29 of four different monomers from the four fulditoxin molecules 
(Figure S7B). Thus, Zn2+ appears to induce the oligomerization of fulditoxin molecules. 
Dynamic light scattering experiments confirmed that fulditoxin exists as a dimer (relative 
molecular mass of 16.1 kDa) in the absence of Zn2+ and as a tetramer of dimers (relative 
molecular mass of 34.3 kDa) in the presence of 3-mM Zn2+. Furthermore, in the presence of 
8-M urea, reduction of the fulditoxin dimer to the monomer species (relative molecular mass 







4 DISCUSSION  
 
In the five decades since the discovery of α-BgTx, the scope of using animal toxins as 
molecular probes for localization and characterization of membrane receptors and ion 
channels and as therapeutic leads for drug discovery has broadened substantially (King, 2011; 
Lewis & Garcia, 2003). Notwithstanding the extensive structure–function analyses done on 
typical snake α-3FNTxs such as α-BgTx, the discovery of α-3FNTxs with novel structural 
characteristics (dimeric α-3FNTxs [Pawlak et al., 2009; Roy et al., 2010]; non-conventional 
α-3FNTxs [Nirthanan, Gopalakrishnakone, Gwee, Khoo, & Kini, 2003]; or toxins with 
unique sequences [Ω-neurotoxins]; Hassan-Puttaswamy, Adams, & Kini, 2015) suggests that 
some α-3FNTxs may interact with nAChRs via different functional sites and display 
selectivity for nAChR subtypes not described previously. Here, we have described the 
discovery, chemical synthesis, and pharmacological and X-ray crystallographic 
characterization of fulditoxin, a structurally unique, homodimeric neurotoxin from coral 
snake (Micrurus fulvius fulvius) venom, which showed high selectivity towards avian muscle 
nAChRs, and broad selectivity for rodent and human muscle and neuronal nAChRs while 
lacking all AA residues critical for binding to nAChRs. It is also the first example of a snake 
dimeric neurotoxin that produced reversible neuromuscular blockade and the first 3FTx to 
show metal binding that enables the formation of a tetrameric complex. 
 
4.1 Fulditoxin is the first dimeric neurotoxin to produce reversible neuromuscular 
blockade 
 
Fulditoxin produced neuromuscular blockade in avian muscle with an IC50 of ~27 nM, 
comparable to potent α-3FNTxs, α-BgTx, and EbTx-b. However, unlike α-BgTx and EbTx-b, 
which produced irreversible ex vivo inhibition of muscle nAChRs, the neuromuscular 
blockade pro- duced by fulditoxin was almost completely and rapidly reversible. This 
atypical reversible neuromuscular blockade has been reported with a few monomeric α-
3FNTxs (Harvey, Hider, Hodges, & Joubert, 1984), notably from the non-conventional α-
3FNTx subfamily which includes candoxin (Bungarus candidus; Nirthanan, Charpantier, et 
al., 2003).  
The mechanism of reversible interaction of snake α-3FNTxs with muscle nAChRs is 
complex and not well understood. Studies on con- ventional monomeric long-chain α-
3FNTxs have found their off-rates from nAChRs to be extremely slow, sometimes lasting 
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days (Young, Herbette, & Skita, 2003), with a half-time for dissociation of the [3H]α-toxin-
Torpedo nAChR-rich membrane complex to be ~60 hr (Weber & Changeux, 1974). 
Therefore, our experimental design using miniaturized organ baths to estimate reversal of α-
3FNTx-induced neuromuscular blockade was limited, given the spontaneous decline in 
contractility of isolated CBCM observed after ~300 min. 
However, reversibility could not simply be attributed to weak or strong binding 
affinities of the toxin to the receptor. For instance, fulditoxin is as potent as α-BgTx and 
EbTx-b in producing neuromuscular blockade in avian muscle but is almost completely 
reversible in its action in contrast to α-BgTx and EbTx-b. Likewise, candoxin is reversible in 
its action at hα1β1δε, but not at hα7 receptors, while binding with nanomolar affinity to both 
subtypes (Nirthanan, Charpantier, et al., 2003). The reversibility of α-3FNTx action has also 
been attributed to a specific site of interaction on the toxin, distinct from its functional site, 
based on multiple sequence analyses which revealed that readily reversible α-3FNTxs lacked 
the conserved Asp31, postulating a role for this residue in determining reversibility (Harvey, 
Hider, Hodges, & Joubert, 1984; Nirthanan, Charpantier, et al., 2003). As fulditoxin binds to 
the ACh-binding pocket (described below) with a yet-to-be-identified, distinct functional site, 
the mecha- nism of fulditoxin's reversible neuromuscular blockade is presently unknown. 
 
4.2 Fulditoxin shows broad selectivity for nAChR subtypes but lacks all functionally 
important AA residues for nAChR recognition 
 
Fulditoxin (native and synthetic) produced comparable blockade of rα1β1δε or hα1β1δε (IC50 
= 2.5 μM) and hα7 (IC50 = 7 μM) nAChRs in electrophysiological experiments. It also 
blocked neuronal hα4β2 (IC50 = 1.8 μM) and hα3β2 (IC50 = 12 μM) receptors, revealing a 
breadth of nAChR selectivity, which is unusual for short-chain α-3FNTxs, that are highly 
selective for muscle nAChRs (Servent et al., 1997). Pairwise alignment of mature protein 
sequences of human β2 and β4 subunits showed 70% homology in the extracellular domain. 
Homology modelling and overlay of their inter-subunit interfaces revealed side-chain 
differences between the non-conserved residues of the β2 and β4 subunits (Cuny, Kompella, 
Tae, Yu, & Adams, 2016). These differences may account for fulditoxin's weak interaction 
with hα4β4 and hα3β4 subtypes in contrast to β2-containing nAChRs. Interestingly, 
fulditoxin shares only ~20% identity (including the eight conserved cysteines) with other 
short-chain α-3FNTxs, as well as with other classes of snake α-3FNTxs, emphasizing its 
structural and func- tional distinctiveness. 
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The AA residues critical for short-chain α-3FNTxs to bind to muscle nAChRs were 
identified as Lys27, Trp29, Asp31, Phe32, Arg33, and Lys47; in addition to residues (His6, 
Gln7, Ser8, Ser9, Gln10, Tyr25, Gly34, Ile36, and Glu38) that play a supporting role (Figure 
S1; Teixeira-Clerc, Menez, & Kessler, 2002). Although fulditoxin competitively inhibits the 
chick muscle nAChR by binding to the ACh-binding site at nanomolar concentrations (Figure 
4e), comparable to prototypical snake α-3FNTxs, none of the previously delineated 
functionally invariant AAs are present in fulditoxin (Figure 2c). Thus, fulditoxin must 
interact with avian nAChRs by utilizing alternative combinations of AA residues to account 
for its potent neuromuscular blockade. 
Differences in assay methods notwithstanding, the affinity of fulditoxin for human 
muscle nAChRs was ~100 times lower compared to avian muscle nAChRs. Mammals are not 
the usual prey for Micrurus spp. which feeds primarily on reptiles including other snakes and 
lizards; and coral snakes themselves are prey for predatory birds (Jack- son & Franz, 1981). 
Therefore, fulditoxin is likely to be optimized to target its natural prey (offence) and 
predators (defence) (Margres, Aronow, Loyacano, & Rokyta, 2013). 
 
4.3 Fulditoxin displays structural plasticity in its three-finger fold 
 
The highly conserved “three-finger” scaffold is held together by eight conserved cysteines 
forming four disulfide linkages at its hydrophobic core, as well as other key AA residues such 
as Tyr25, Gly40, Pro44, Pro48, Arg39, and Glu58, integral to its structural stability (Kini & 
Doley, 2010; Ricciardi et al., 2000; Tsetlin, 2015). Fulditoxin, however, retains just the eight 
conserved cysteines, lacking all the other struc- turally invariant AA residues, suggesting that 
the four disulfide bonds are sufficient to retain its three-finger structure. Furthermore, struc- 
tural plasticity in the loop regions of 3FTxs permits the adoption of a variety of functional 
conformations in order to interact with different pharmacological targets (Ricciardi et al., 
2000). In this context, fulditoxin has a longer loop III (Figure 2c) and shows conformational 
differences at the tip of loop II (Figure 5e), suggesting that these fundamental structural 








4.4 Fulditoxin forms a distinct dimer primarily through hydrophobic interactions 
 
The elution on size-exclusion chromatography (Figure 1a), dynamic light scattering (Figure 
S7C), and crystal structure (Figure 5a–c) of fulditoxin indicated that it exists as a non-
covalent homodimer of two short-chain α-3FNTx monomers. This dimer formation is distinct 
from other non-covalent α-3FNTx homodimers, such as κ-neurotoxins and haditoxin 
composed of long-chain and short-chain α-3FNTx monomers respectively. κ-Neurotoxins 
and haditoxin share a similar quaternary structure, with their two monomeric units held in an 
antiparallel orientation through extensive hydrogen bonding between their loop III β-strands 
(Figure 6; Dewan, Grant, & Sacchettini, 1994; Roy et al., 2010). In contrast, the fulditoxin 
dimer is held together primarily by 29 hydrophobic interactions between AA residues from 
loop II; and only three side chain–side chain hydrogen bonding contacts. 
A BLAST search revealed that the AA residues involved in dimerization of fulditoxin 
are conserved among other Micrurus 3FTxs (Figure 2a). Hence, we propose that these 
Micrurus 3FTxs are also likely to form non-covalent dimers, and fulditoxin is the first 
member of this new subfamily of dimeric α-3FNTxs. 
 
4.5 Effects of dimerization on the pharmacology of fulditoxin 
 
Typical monomeric short-chain α-3FNTxs like EbTx-a and EbTx-b have been shown to be 
selective and potent blockers of muscle nAChRs while being ineffective at neuronal nAChRs 
(Kessler, Mar- chot, Silva, & Servent, 2017; Servent et al., 1997). In contrast, haditoxin, a 
homodimer of short-chain α-3FNTxs, inhibits both muscle α1β1γδ as well as neuronal α7, 
α3β2, and α4β2 nAChRs (Roy et al., 2010). Fulditoxin, also a homodimer of short-chain α-
3FNTxs, albeit with a significantly different quaternary structure, exhibits nanomolar and 
micromolar affinity for chick and mammalian muscle nAChRs, respectively, in addition to 
inhibiting several neuronal nAChR subtypes. Thus, dimerization appears to expand the 
selectivity of short- chain α-3FNTxs for nAChRs. 
Besides non-covalent α-3FNTx dimers like haditoxin and fulditoxin, covalent dimers 
where α-3FNTx monomers are linked by intermolecular disulfide bonds have also been 
reported (Figure 2d; Table 2; Osipov et al., 2012; Pawlak et al., 2009). Dimeric α-cobratoxin 
(Naja kaouthia) developed the additional capacity to block neuronal α3β2 nAChRs, unlike 
monomeric α-cobratoxin that is restricted to targeting only muscle and α7 nAChRs (Osipov 
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et al., 2012). The covalently linked heterodimeric α-3FNTx, irditoxin (Boiga irregularis), 
exhibits taxa-specific neurotoxicity for avian α1β1γδ nAChRs representing the usual prey of 
this arboreal species (Pawlak et al., 2009). Therefore, dimeric α-3FNTxs represent a 
structurally heterogeneous group of unique snake toxins (Figure 6) exhibiting different 
receptor specificities from that expected for their monomeric components. Hence, we propose 
that dimerization is likely to present novel structural conformations for α-3FNTxs to enable 





Figure 6 Structures of dimeric three-finger neurotoxins. (A) Non-covalently linked 
homodimers -bungarotoxin (Bungarus multicinctus; Elapidae; 1KBA), haditoxin 
(Opiophagus hannah; Elapidae; 3HH7), and fulditoxin (Micrurus fulvius; Elapidae). (B) 
Covalently linked heterodimer irditoxin (Boiga irregularis; Colubridae; 2H7Z) and 
covalently linked homodimeric α-cobratoxin (Naja kaouthia; Elapidae; 4AEA). The figures 
were generated using the respective PDB structures (accession number indicated in 
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parenthesis) of each toxin. The species and family of the source are indicated. Disulfide 






Table 2: Selected dimeric snake three-finger neurotoxins that interact with nicotinic acetylcholine receptors  
Dimeric toxin Dimeric linkage Monomeric subunit nAChR activity Source References 








Muscle (α1β1εδ)(IC50 = 2.6 µM) 
α3β2 (IC50 = 12.6 µM)  
α7 (IC50 = 7 µM)  
α4β2 (1.8 µM) 
Eastern coral snake 






9 hydrogen bonds Long-chain 3Fα-NTxs 
α3β2 (IC50 = 3 nM)  
α7 (weak inhibition)  
α4β2 (weak inhibition) 
Taiwanese multi-banded krait 
Bungarus multicinctus 
(Elapidae) 
(Osipov et al., 2008) 
Haditoxin Non-covalent 
14 hydrogen bonds Short-chain 3Fα-NTxs 
α7 (IC50 = 0.2 µM) 
Muscle (α1β1γδ)(IC50 = 0.5 µM) 
α3β2 (IC50 = 0.50 µM) 
α4β2- (IC50 = 2.60 µM) 
King cobra  
Ophiophagus hannah 
(Elapidae) 
(Roy et al., 2010) 







Avian muscle (α1β1γδ)(IC50 = 10 nM) 
Rat muscle (α1β1γδ) (IC50 > 10 µM) 
Brown tree snake 
Boiga irregularis  
(Colubridae) 








NTxs in combination 
with cytotoxins) 
Torpedo (α1β1γδ) (IC50 = 10 nM)  
α7 (IC50 = 0.2 µM) 
α3β2 (IC50 = 0.15 µM) 
Monocellate cobra 
Naja kaouthia  
(Elapidae) 
(Osipov et al., 2012) 
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4.6 Fulditoxin is the first metal-binding 3FTx 
 
Four dimeric fulditoxin molecules coalesced and formed a tetrameric complex around two 
Zn2+ atoms, with each Zn2+ atom coordinated with four His29 residues at the tip of loop II 
(Figure S7B). Metal-binding proteins in snake venom are predominantly enzymes whose 
catalytic activity involves zinc. Metals can also stabilize the conformation of proteins and 
contribute to their function (Moroz et al., 2009). Fulditoxin is the first 3FTx to show metal-
binding capability. Interestingly, His29 is conserved in some 3FTxs from M. fulvius (Figure 
2a), and a histidine is also present at the tip of loop II of Ω-neurotoxins (Hassan-Puttaswamy, 
Adams, & Kini, 2015), suggesting that these 3FTXs may also undergo Zn2+-coordinated 
tetramerization. 
Analytical size-exclusion chromatography of fulditoxin at pharmacologically relevant 
concentrations in the presence of Zn2+ showed that it existed in the native dimeric species, 
suggesting that zinc-induced oligomerization is likely to be concentration-dependent and may 
occur only at fulditoxin concentrations above 5 mg·ml−1, which is functionally 
inconsequential since fulditoxin produced neuromuscular blockade at nanomolar 
concentrations (IC50  values  about  10  nM; 69 ng·ml−1). 
 
4.7 Fulditoxin constitutes a new class of nAChR- targeting neurotoxins 
 
Altogether, fulditoxin is structurally and functionally distinct from other nAChR-targeting 
snake neurotoxins. We propose that fulditoxin and other Micrurus toxins identified through 
transcriptomic analysis of venom glands (Correa-Netto et al., 2011; Guerrero-Garzon et al., 
2018; Margres, Aronow, Loyacano, & Rokyta, 2013; Figure 2a) belong to a new class of 
nAChR-targeting neurotoxins which we named Σ-neurotoxins. 
Snake 3FTxs utilize a common protein scaffold to target a variety of molecular targets 
and exhibit diverse biological effects, underpin- ning functional evolutionary divergence 
(Kini, 2011; Kini & Doley, 2010). Interestingly, structurally distinct protein scaffolds can 
also exhibit functional similarity through convergent evolution (Tsetlin, 2015), including 
animal toxins such as monomeric/dimeric α-3FNTxs, waglerins, PLA2, azemiopsin, Ω-
neurotoxins, and α-conotoxins, which have significantly diverse structures but bind to the 
ACh-binding pocket of nAChRs (Kini, 2011; Kini & Doley, 2010). Hence, Σ-neuro- toxins 
represented by fulditoxin, while retaining the protein scaffold of α-3FNTxs, use a yet-to-be 
determined pharmacophore to bind to the ACh-binding pocket of the nAChR in another 
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example of evolu- tionary functional convergence. Σ-neurotoxins offer new tools for studying 
nAChR subtypes, as well as greater insight into interactions between peptide antagonists and 
nAChRs. 
In conclusion, fulditoxin is a novel homodimeric short-chain α-3FNTx held together 
primarily by hydrophobic interactions and able to form a tetrameric complex by binding Zn2+, 
the first report of metal-binding capability for the 3FTx family. Fulditoxin exhibited broad 
spectrum inhibition of α1β1δε, α4β2, α7, and α3β2 nAChRs and produced postsynaptic 
neuromuscular blockade at nanomolar concentrations, which was completely reversible in 
contrast to typical α-3FNTxs. Furthermore, fulditoxin competitively antagonized muscle 
nAChRs at the ACh-binding site despite lacking all canonical α-3FNTx functional AA 
residues, suggesting that this toxin used a novel and different pharmacophore for its 
interaction with nAChRs. This is an example of unusual functional convergence in evolution, 
in contrast to the characteristic functional divergence seen within the 3FTx family. 
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